Aberdeen Group plc Makes New $925,000 Investment in Avalo Therapeutics, Inc. $AVTX

Aberdeen Group plc acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 72,800 shares of the company’s stock, valued at approximately $925,000. Aberdeen Group plc owned approximately 0.55% of Avalo Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in shares of Avalo Therapeutics in the second quarter valued at $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth $56,000. Geode Capital Management LLC lifted its holdings in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after buying an additional 2,648 shares in the last quarter. Velan Capital Investment Management LP boosted its position in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock valued at $773,000 after buying an additional 43,000 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after acquiring an additional 400,898 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on AVTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Guggenheim assumed coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective on the stock. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.88.

Avalo Therapeutics Trading Down 11.0%

Shares of AVTX opened at $14.21 on Friday. The firm has a market cap of $263.03 million, a price-to-earnings ratio of -2.65 and a beta of 0.88. The stock has a 50 day moving average of $16.30 and a 200-day moving average of $14.68. Avalo Therapeutics, Inc. has a 52 week low of $3.39 and a 52 week high of $20.72.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.